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Anaplastic thyroid carcinoma (ATC) is one of the most
lethal human malignancies, with a median overall survival
of less than six months. While most of the genetic muta-
tions occurring in papillary thyroid carcinoma (PTC) were
recently discovered through an integrated genomic approach,
molecular genetics of ATC is still in part unknown. ATC
is refractory to conventional therapies, including surgery,
chemotherapy, radiotherapy, and radioiodine therapy. New
target agents are currently being evaluated in clinical trials.
Under this frame, there is an urgent need to investigate the
molecular biology and the therapeutic opportunities of this
understudied, rare cancer.
The aim of this special issue is to gather a collection
of papers focusing on molecular tools for diagnosis and
therapy of anaplastic thyroid carcinoma. The issue contains
eight papers including four review articles and four research
papers.
The review article of C. S. Fuziwara and E. T. Kimura
analyzes the role of miRNA in anaplastic thyroid carcinoma.
miRNAs are a class of small noncoding RNAs that regulate
posttranscriptional gene expression. Increasing evidences
show that they may drive oncogenesis. The article under-
scores the families of miRNA that are deregulated in ATC,
namely, the miR-200 family, miR-30 family, let-7 family, miR
17–92 cluster, miR-146a/b, and miR 221/222. Modulation of
miRNA levels, using miRNAmimics or anti-miRs, may open
new therapeutic options for ATC.
In the review article of M. Ragazzi et al. the focus is on
the histopathology of ATC.The authors discussed the typical
molecular features ofATC cells, with an elegant description of
the main histological subtypes and the differential diagnostic
criteria. The review included also an update of the molecular
genetics of ATC.
The other two review articles included in the special issue
focus on new proteins overexpressed in ATC, which may
represent novel therapeutic targets, that is, Aurora kinases
and transferrin receptor.
In detail, the work of E. Baldini et al. focuses on Aurora
kinases in ATC. The review is a comprehensive update
of the structure, expression, localization, and functions of
Aurora proteins and their role in human cancers. Further, the
review summarizes the findings, mainly made by the authors
group, of Aurora kinases in thyroid cancers. Importantly,
preclinical data indicate that Aurora kinase inhibitors may
have a therapeutic potential for ATC treatment.
The review of R. Parenti et al. focuses on type 1 trans-
ferrin receptor (TfR1/CD71) in ATC. The TfR1/CD71 is a
cell membrane glycoprotein involved in iron homeostasis
and cell growth. The authors showed immunohistochemical
data demonstrating the overexpression of TfR1/CD71 in
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ATC. They discuss the opportunities to target TfR1/CD71
by monoclonal or recombinant antibodies or transferrin-
gallium-TfR1/CD71molecular complexes or small interfering
RNAs (siRNAs).
Four research articles are included in the special issue.
Two of these articles are from the group of Sipetic. In the
first research paper, V. Zivaljevic et al. analyze the risk factors
for ATC. The study, done on 126 ATC patients, showed that
independent risk factors forATC are low education level, type
B blood group, and goitre. A similar study, included in the
special issue, from the same group of authors, addresses the
importance of age in patient survival.The study demonstrates
that the best prognosis for ATC is in patients younger than 50
years old.
In the research article by F. Baldan et al. the synergy
between HDAC inhibitors and PARP inhibitors has been
investigated in an ATC-derived cell line SW1736.The authors
showed that both compounds synergize in activation of
apoptosis and induction of thyroid-specific gene expression.
Thus, this work suggests that the combined use of HDAC
and PARP inhibitors may be a useful strategy for treatment
of ATC.
Finally, W. Arancio and et al. conducted a competing
endogenous RNA analysis to investigate the role of the stem
cell factor SOX2 in ATC cell lines. The authors identified
a functional network of SOX2 interactors including genes
involved in the biogenesis ofmicroRNAs (DICER1, RNASEN,
andEIF2C2), in the control cell cycle (TP53 andCCND1), and
in mitochondrial activity (COX8A).
In conclusion, within this special issue, we gather articles
underlining several aspects of molecular biology and thera-
peutic options for ATC. We hope that this special issue could
contribute to the advancement of the knowledge of this rare
and aggressive cancer.
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